ArticleNPJ precision oncology2024

Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer.

Nicholas Mai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.